Combined chemoradiotherapy for early glottic cancer in clinical practice in Japan: Analysis of 10 institutions

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5181-5184

  Itoh, Yoshiyuki ^a   Hirasawa, Naoki ^a   Naganawa, Shinji ^a   Ishihara, Shunichi ^a   Suzuki, Kazunori ^b   Koyama, Kazuyuki ^c   Murao, Takayuki ^d   Asano, Akiko ^e   Nomoto, Yoshito ^f   Horikawa, Yoshimi ^g   Sasaoka, Masahiro ^h   Obata, Yasunori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tajimi Prefectural Hospital   (Japan)

^d Ichinomiya Municipal Hospital   (Japan)

^e TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^f MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Kainan Hospital   (Japan)

^h Department of Radiology   (Japan)

Author keywords

Chemotherapy; Glottic cancer; Radiotherapy; Vocal cord cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; UFT;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; CLINICAL PRACTICE; DRUG MEGADOSE; EARLY CANCER; FEMALE; HUMAN; JAPAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; GLOTTIS; HUMANS; JAPAN; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; TEGAFUR; URACIL;

EID: 78751563926     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Head and Neck Cancers, v.2.2010. http://www.nccn.org/professionals/ physician-gls/PDF/head-and-neck.pdf (accessed 11/10/2010).
2. Pfister DG, Laurie SL, Weinstein GS, Mendennhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Leupold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA and Wolf GT: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24: 3693-3704, 2006.
3. International Union Against Cancer. TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss, 2002.
4. Tanisada K, Teshima T, Ohno Y, Inoue T, Abe M, Ikeda H, Owen JB, Hanks GE, Masuda K and Honke Y: Patterns of care study: quantitative evaluation of the quality of radiotherapy in Japan. Cancer 95: 164-171, 2002.
5. Garden AS, Morrison WH and Ang KK: Larynx and hypopharynx cancer. In: Clinical Radiation Oncology. Gunderson LL and Tepper J (eds.). Churchill Livingstone, Elsevier, pp. 727-753, 2007.
6. Mendenhall WM, Hinerman RW, Amdur RJ, Mancuso AA, Villaret DB and Werning JW: Larynx. In: Perez and Brady's Principles and Practice of Radiation Oncology. Halperin EC, Perez CA and Brady LW (eds). Philadelphia: Lippincott Williams & Wilkins, pp. 975-995, 2008.
7. Mendenhall WM, Amdur RJ, Morris CG and Hinerman RW: T12N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19: 4029-4036, 2001.
8. Yamazaki H, Nishiyama K, Tanaka E, Koizumu M and Chatani M: Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64: 77-82, 2006.
9. Haugen H, Johansson K-A and Mercke C: Hyperfractionaccelerated or conventionally fractioned radiotherapy for early glottic cancer. Int J Radiat Oncol Biol Phys 52: 109-119, 2002.
10. Garden AS, Forster K, Wong P, Morrison W, Schechter NR and Ang KK: Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 55: 322-328, 2003.
11. Trotti A, Pajak T, Emami B, Hammond E, Jones C, Morrison W, Sagar S, Ridge J, Fu KK and Ang K: A randomized trial of hyperfractionation versus standard fractionation in T2 squamous cell carcinoma of the vocal cord. Int J Radiat Oncol Biol Phys 66: S15, 2006. (abstract)
12. Hirasawa N, Itoh Y, Naganawa S, Ishihara S, Suzuki K, Nomoto Y, Murao T, Horikawa Y, Koyama K, Sasaoka M, Asano A and Obata Y: The results of 29 respondent otolaryngologists to questionnaires for strategy of early glottic cancer. Jpn J Clin Radiol 55: 541-546, 2010 (in Japanese with English summary).
13. Jin J, Liao Z, Gao L, Huang X and Xu G: Analysis of prognostic factors for T1N0M0 glottic cancer treated with definitive radiotherapy alone: experience of the Chinese Academy of Medical Science. Int J Radiat Oncol Biol Phys 54: 471-478, 2002.
14. Dinshaw KA, Sharma V, Agarwal JP, Ghosh S and Havaldar R: Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications. Int J Radiat Oncol Biol Phys 48: 723-735, 2000.
15. Cellai E, Frata P, Magrini SM, Paiar F, Barca R, Fondelli S, Polli C, Livi L, Bonetti B, Vitali E, De Stefani A, Bluglione M and Biti G: Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0M0 disease. Int J Radiat Oncol Biol Phys 63: 1378-1386, 2005. (Pubitemid 41628032)
16. Frata P, Cellai E, Magrini SM, Paiar F, Barca R, Fondelli S, Polli C, Livi L, Bonetti B, Vitali E, De Stefani A, Bluglione M and Biti G: Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. the case of T2N0M0 disease. Int J Radiat Oncol Biol Phys 65: 1387-1394, 2005. (Pubitemid 41628033)
17. Reddy SP, Hong RL, Nagda S and Emami B: Effect of tumor bulk on local control and survival of patients with T1 glottic cancer: a 30-year experience. Int J Radiat Oncol Biol Phys 69: 1389-1394, 2007.
18. Narayana A, Vaughan ATM, Kathuria S, Fisher SG, Walter SA and Reddy SP: P53 overexpression is associated with bulky tumor and poor local control in T1 glottic glottic cancer. Int J Radiat Oncol Biol Phys 46: 21-26, 2000.
19. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee D, Leaf A, Ensley J and Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003.
20. Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Nimomiya H, Chikamatsu K, Furuya N, Hayakawa K, Mitsuhashi N and Nakano T: Radiation therapy for T2N0 laryngeal cancer: a retrospective analysis for the impact of concurrent chemotherapy on local control. Int J Radiat Oncol Biol Phys 64: 995-1001, 2006.
21. Itoh Y and Fuwa N: Retrospective analysis: concurrent chemotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Radiat Med 24: 277-281, 2006. (Pubitemid 351194323)
22. Kumamoto Y, Masuda M, Kuratomi Y, Toh S, Shinokuma A, Chujo K, Yamamoto T and Komiyama S: 'FAR' chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck 24: 637-642, 2002.
23. Tsuji H, Kiba T, Nagata M, Inoue T, Yukawa H, Yamashita T, Shimode Y, Murata H, Nagata K and Tomoda K: A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology 71: 369-373, 2006. (Pubitemid 47573699)
24. Niibe Y, Nakayama M, Matsubayasi T, Takahashi H, Kitano M, Okamoto M and Hayakawa K: Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan. Anticancer Res 27: 3497-3500, 2006.
25. Chera B, Amdur PJ, Morris CG, Kirwan JM and Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010 (in press).